Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Axsome Therapeutics Inc
AXSM
Healthcare
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor...
antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:AXSM)
New Post
View:
Posts & Comments
Threaded Posts
(88)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 20, 2024 7:15pm
Neurology-Focused Axsome Therapeutics Reports Deeper Than Ex
NEWS: $AXSM Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones | BenzingaAxsome Therapeutics Inc@(NASDAQ:AXSM) reported fourth-quarter
...more
(88)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 20, 2024 7:00pm
Axsome Therapeutics Reports Fourth Quarter and Full Year 202
BREAKING NEWS: $AXSM Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateTotal 4Q and full year 2023 net product revenue of $71.5 million and
...more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Jun 22, 2021 8:37am
5 MOST PROMISING ALZHEIMER’S DISEASE STOCK!
5 MOST PROMISING ALZHEIMER’S DISEASE STOCK! https://www.aviseanalytics.com/5-most-promising-alzheimers-disease-stock/
(24)
•••
Marphine
X
View Profile
View Bullboard History
Comment by
Marphine
on Feb 12, 2021 7:35pm
RE:Awesome Run to Over $100 USD
Now 74$. First over 100 soon then?
(8)
•••
winemerlotcab67
X
View Profile
View Bullboard History
Post by
winemerlotcab67
on Feb 23, 2020 6:30pm
Awesome Run to Over $100 USD
We did great buying below $10 We think GNPX will do the same if not better :-) Same pattern https://finance.yahoo.com/quote/GNPX?p=GNPX Do your own DD Happy Investing
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon